RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.
Read original at benzingaStocks · News reference
Biogen Lowers FY2026 Adj EPS Guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 Est
Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 analyst estimate..
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 10:16 AM
- Checked
- Jul 29, 2026, 10:15 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease
Read original at benzingaWolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.
Read original at benzingaBiogen Completes Acquisition of RayThera Inc.
Biogen Inc. announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company specializing in small-molecule immunology therapies. The acquisition adds multiple assets to Biogen's immunology portfolio, with the lead program entering Phase 1 development in July 2026. The company views this as part of its strategic growth in immunology and its open innovation model.
Read original at globenewswire-inc